We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Tekmira Pharmaceuticals Completes ApoB SNALP Phase 1 Clinical Trial

News   Jan 11, 2010

 
Tekmira Pharmaceuticals Completes ApoB SNALP Phase 1 Clinical Trial
 
 
 

RELATED ARTICLES

Reducing Heart Attack-induced Tissue Damage by 30%

News

Scientists have discovered that inhibiting the synthesis of a lipid in a mouse suffering a heart attack reduces the tissue damage by 30%.

READ MORE

It's Time to Keep Check on the Microbiome

News

Scientists have developed a novel technique based on an oscillating gene circuit that they hope will help to shed light on the human microbiome.

READ MORE

Drug Prevents Liver Scarring in People With HIV

News

A new study reports that the injectable hormone tesamorelin reduces liver fat and prevents liver fibrosis (scarring) in people living with HIV.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery Genomics Research Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE